Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer

Cancer Biology and Therapy

Volumn 16, Issue 11, 2015, Pages 1604-1615

  Kokabee, Leila ^a,b   Wang, Xianhui ^a   Sevinsky, Christopher J ^a   Wang, Wei Lin Winnie ^a   Cheu, Lindsay ^a   Chittur, Sridar V ^a   Karimipoor, Morteza ^b   Tenniswood, Martin ^a   Conklin, Douglas S ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

apoptosis; biomarker; BTK inhibitors; cell survival; prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CGI 1746; IBRUTINIB; SPEBRUTINIB; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; APOPTOSIS REGULATORY PROTEIN; ISOENZYME; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LNCAP CELL LINE; MICROARRAY ANALYSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATIC NEOPLASMS; PROTEIN PROCESSING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION; HUMANS; ISOENZYMES; MALE; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; UP-REGULATION;

EID: 84948564584     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1078023     Document Type: Article

References (48)

1. S.F.Altekruse, L.Huang, J.E.Cucinelli, T.S.McNeel, K.M.Wells, M.N.Oliver. Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States, 1999-2001. Cancer Epidemiol Biomarkers Prev 2010; 19:1460-7; http://dx.doi.org/10.1158/1055-9965.EPI-09-1310
2. A.Akinleye, Y.Chen, N.Mukhi, Y.Song, D.Liu. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013; 6:59; PMID:23958373; http://dx.doi.org/10.1186/1756-8722-6-59
3. B.Lee, N.Mukhi, D.L.Liu. Current management and novel agents for malignant melanoma. J Hematol Oncol 2012; 5:3; http://dx.doi.org/10.1186/1756-8722-5-3
4. J.M.Stommel, A.C.Kimmelman, H.Ying, R.Nabioullin, A.H.Ponugoti, R.Wiedemeyer, A.H.Stegh, J.E.Bradner, K.L.Ligon, C.Brennan, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318:287-90; PMID:17872411; http://dx.doi.org/10.1126/science.1142946
5. P.Blume-Jensen, T.Hunter. Oncogenic kinase signalling. Nature 2001; 411:355-65; PMID:11357143; http://dx.doi.org/10.1038/35077225
6. A.O.Vassilev, F.M.Uckun. Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). Curr Pharm Des 2004; 10:1757-66; PMID:15180538; http://dx.doi.org/10.2174/1381612043384475
7. D.S.Krause, R.A.Van Etten. Tyrosine kinases as targets for cancer therapy. N Eng J Med 2005; 353:172-87; PMID:16014887; http://dx.doi.org/10.1056/NEJMra044389
8. J.Baselga. Targeting tyrosine kinases in cancer: the second wave. Science 2006; 312:1175-8; PMID:16728632; http://dx.doi.org/10.1126/science.1125951
9. A.Arora, E.M.Scholar. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315:971-9; PMID:16002463; http://dx.doi.org/10.1124/jpet.105.084145
10. C.Eifert, X.Wang, L.Kokabee, A.Kourtidis, R.Jain, M.J.Gerdes, D.S.Conklin. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer 2013; 52:961-75; http://dx.doi.org/10.1002/gcc.22091
11. C.I.Smith, B.Baskin, P.Humire-Greiff, J.N.Zhou, P.G.Olsson, H.S.Maniar, P.Kjellén, J.D.Lambris, B.Christensson, L.Hammarström. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively downregulated in T lymphocytes and plasma cells. J Immunol 1994; 152:557-65
12. M.de Weers, M.C.Verschuren, M.E.Kraakman, R.G.Mensink, R.K.Schuurman, J.J.van Dongen, R.W.Hendriks. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 1993; 23:3109-14; PMID:8258324; http://dx.doi.org/10.1002/eji.1830231210
13. A.J.Mohamed, L.Yu, C.M.Backesjo, L.Vargas, R.Faryal, A.Aints, B.Christensson, A.Berglöf, M.Vihinen, B.F.Nore, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009; 228:58-73; PMID:19290921; http://dx.doi.org/10.1111/j.1600-065X.2008.00741.x
14. J.J.Buggy, L.Elias. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012; 31:119-32; PMID:22449073; http://dx.doi.org/10.3109/08830185.2012.664797
15. T.Kurosaki, S.Tsukada. BLNK: connecting Syk and Btk to calcium signals. Immunity 2000; 12:1-5; PMID:10661400; http://dx.doi.org/10.1016/S1074-7613(00)80153-3
16. T.Kurosaki. Regulation of B-cell signal transduction by adaptor proteins. Nat Rev Immunol 2002; 2:354-63; PMID:12033741; http://dx.doi.org/10.1038/nri801
17. U.Schmidt, N.Boucheron, B.Unger, W.Ellmeier. The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol 2004; 134:65-78; PMID:15133303; http://dx.doi.org/10.1159/000078339
18. O.J.D'Cruz, F.M.Uckun. Novel Bruton's tyrosine kinase inhibitors currently in development. Onco Targets Ther 2013; 6:161-76; PMID:23493945
19. D.J.Rawlings. Bruton's tyrosine kinase controls a sustained calcium signal essential for B lineage development and function. Clin Immunol 1999; 91:243-53; PMID:10370369; http://dx.doi.org/10.1006/clim.1999.4732
20. S.H.Lee, T.Kim, D.Jeong, N.Kim, Y.Choi. The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation. J Biol Chem 2008; 283:11526-34; PMID:18281276; http://dx.doi.org/10.1074/jbc.M708935200
21. M.Shinohara, B.Y.Chang, J.J.Buggy, Y.Nagai, T.Kodama, H.Asahara, H.Takayanagi. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. Bone 2014; 60:8-15; PMID:24316417; http://dx.doi.org/10.1016/j.bone.2013.11.025
22. S.E.Herman, A.L.Gordon, E.Hertlein, A.Ramanunni, X.Zhang, S.Jaglowski, J.Flynn, J.Jones, K.A.Blum, J.J.Buggy, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117:6287-96; PMID:21422473; http://dx.doi.org/10.1182/blood-2011-01-328484
23. R.W.Hendriks, S.Yuvaraj, L.P.Kil. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer 2014; 14:219-32; PMID:24658273; http://dx.doi.org/10.1038/nrc3702
24. W.Guo, R.Liu, G.Bhardwaj, J.C.Yang, C.Changou, A.H.Ma, A.Mazloom, S.Chintapalli, K.Xiao, W.Xiao, et al. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis 2014; 5:e1409; PMID:25188519; http://dx.doi.org/10.1038/cddis.2014.343
25. Y.T.Tai, B.Y.Chang, S.Y.Kong, M.Fulciniti, G.Yang, Y.Calle, Y.Hu, J.Lin, J.J.Zhao, A.Cagnetta, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120:1877-87; PMID:22689860; http://dx.doi.org/10.1182/blood-2011-12-396853
26. J.A.Burger, J.J.Buggy. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 2013; 54:2385-91; PMID:23425038; http://dx.doi.org/10.3109/10428194.2013.777837
27. J.Hutcheson, K.Vanarsa, A.Bashmakov, S.Grewal, D.Sajitharan, B.Y.Chang, J.J.Buggy, X.J.Zhou, Y.Du, A.B.Satterthwaite, et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther 2012; 14:R243; PMID:23136880; http://dx.doi.org/10.1186/ar4086
28. E.M.Ruderman, R.M.Pope. More than just B-cell inhibition. Arthritis Res Ther 2011; 13:125; PMID:21878134; http://dx.doi.org/10.1186/ar3439
29. L.A.Honigberg, A.M.Smith, M.Sirisawad, E.Verner, D.Loury, B.Chang, S.Li, Z.Pan, D.H.Thamm, R.A.Miller, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010; 107:13075-80; PMID:20615965; http://dx.doi.org/10.1073/pnas.1004594107
30. Z.Pan, H.Scheerens, S.J.Li, B.E.Schultz, P.A.Sprengeler, L.C.Burrill, R.V.Mendonca, M.D.Sweeney, K.C.Scott, P.G.Grothaus, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007; 2:58-61; PMID:17154430; http://dx.doi.org/10.1002/cmdc.200600221
31. H.Eda, L.Santo, D.D.Cirstea, A.J.Yee, T.A.Scullen, N.Nemani, Y.Mishima, P.R.Waterman, S.Arastu-Kapur, E.Evans, et al. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia 2014; 28:1892-901; PMID:24518207; http://dx.doi.org/10.1038/leu.2014.69
32. J.A.Di Paolo, T.Huang, M.Balazs, J.Barbosa, K.H.Barck, B.J.Bravo, R.A.Carano, J.Darrow, D.R.Davies, L.E.DeForge, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 2011; 7:41-50; PMID:21113169; http://dx.doi.org/10.1038/nchembio.481
33. W.Huang da, B.T.Sherman, R.A.Lempicki. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37:1-13; PMID:19033363; http://dx.doi.org/10.1093/nar/gkn923
34. J.Baumann, C.Sevinsky, D.S.Conklin. Lipid biology of breast cancer. Biochimica Biophys Acta 2013; 1831:1509-17; PMID:23562840; http://dx.doi.org/10.1016/j.bbalip.2013.03.011
35. P.W.Hochachka, J.L.Rupert, L.Goldenberg, M.Gleave, P.Kozlowski. Going malignant: the hypoxia-cancer connection in the prostate. Bioessays 2002; 24:749-57; PMID:12210536; http://dx.doi.org/10.1002/bies.10131
36. S.G.Landt, G.K.Marinov, A.Kundaje, P.Kheradpour, F.Pauli, S.Batzoglou, B.E.Bernstein, P.Bickel, J.B.Brown, P.Cayting, et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res 2012; 22:1813-31; PMID:22955991; http://dx.doi.org/10.1101/gr.136184.111
37. B.Y.Chang, M.M.Huang, M.Francesco, J.Chen, J.Sokolove, P.Magadala, W.H.Robinson, J.J.Buggy. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011; 13:R115; PMID:21752263; http://dx.doi.org/10.1186/ar3400
38. E.K.Evans, R.Tester, S.Aslanian, R.Karp, M.Sheets, M.T.Labenski, S.R.Witowski, H.Lounsbury, P.Chaturvedi, H.Mazdiyasni, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther 2013; 346:219-28; PMID:23709115; http://dx.doi.org/10.1124/jpet.113.203489
39. P.J.Kowalski, M.A.Rubin, C.G.Kleer. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003; 5:R217-22; PMID:14580257; http://dx.doi.org/10.1186/bcr651
40. J.Paredes, A.Albergaria, J.T.Oliveira, C.Jeronimo, F.Milanezi, F.C.Schmitt. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 2005; 11:5869-77; PMID:16115928; http://dx.doi.org/10.1158/1078-0432.CCR-05-0059
41. K.Chu, C.J.Cheng, X.Ye, Y.C.Lee, A.J.Zurita, D.T.Chen, L.Y.Yu-Lee, S.Zhang, E.T.Yeh, M.C.Hu, et al. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 2008; 6:1259-67; PMID:18708358; http://dx.doi.org/10.1158/1541-7786.MCR-08-0077
42. S.Ortolano, I.Y.Hwang, S.B.Han, J.H.Kehrl. Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol 2006; 36:1285-95; PMID:16619289; http://dx.doi.org/10.1002/eji.200535799
43. K.H.Tsui, Y.L.Chang, T.H.Feng, P.L.Chang, H.H.Juang. Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells. Prostate 2012; 72:1431-42; PMID:22290289; http://dx.doi.org/10.1002/pros.22494
44. L.Schaefer, L.Evan, J.Whiteford, D.Dyer, D.Rowan. Cell signalling in inflammation. Int J Exp Pathol 2011; 92:A6-A7
45. E.Currie, A.Schulze, R.Zechner, T.C.Walther, R.V.Farese, Jr. Cellular fatty acid metabolism and cancer. Cell Metab 2013; 18:153-61; PMID:23791484; http://dx.doi.org/10.1016/j.cmet.2013.05.017
46. J.M.Silva, M.Z.Li, K.Chang, W.Ge, M.C.Golding, R.J.Rickles, D.Siolas, G.Hu, P.J.Paddison, M.R.Schlabach, et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 2005; 37:1281-8; PMID:16200065
47. Y.Benjamini, Y.Hochberg. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met 1995; 57:289-300
48. D.Y.Lin. An efficient Monte Carlo approach to assessing statistical significance in genomic studies. Bioinformatics 2005; 21:781-7; PMID:15454414; http://dx.doi.org/10.1093/bioinformatics/bti053